Clinical Trial Update: Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating cessation of somatostatin analogue therapy after PRRT in midgut, hindgut, and pancreatic neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• SOMATULINE DEPOT (LANREOTIDE ACETATE)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Neuroendocrine Tumors | Phase 2 | Status: RECRUITING